IL275423A - Methods and compositions for inducing an immune response against hepatitis b virus (hbv) - Google Patents

Methods and compositions for inducing an immune response against hepatitis b virus (hbv)

Info

Publication number
IL275423A
IL275423A IL275423A IL27542320A IL275423A IL 275423 A IL275423 A IL 275423A IL 275423 A IL275423 A IL 275423A IL 27542320 A IL27542320 A IL 27542320A IL 275423 A IL275423 A IL 275423A
Authority
IL
Israel
Prior art keywords
hbv
virus
inducing
compositions
methods
Prior art date
Application number
IL275423A
Other languages
Hebrew (he)
Original Assignee
Bavarian Nordic As
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As, Janssen Sciences Ireland Unlimited Co filed Critical Bavarian Nordic As
Publication of IL275423A publication Critical patent/IL275423A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
IL275423A 2017-12-19 2020-06-16 Methods and compositions for inducing an immune response against hepatitis b virus (hbv) IL275423A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607439P 2017-12-19 2017-12-19
IB2017058148 2017-12-19
PCT/IB2018/060257 WO2019123250A1 (en) 2017-12-19 2018-12-18 Methods and compositions for inducing an immune response against hepatitis b virus (hbv)

Publications (1)

Publication Number Publication Date
IL275423A true IL275423A (en) 2020-08-31

Family

ID=65201641

Family Applications (1)

Application Number Title Priority Date Filing Date
IL275423A IL275423A (en) 2017-12-19 2020-06-16 Methods and compositions for inducing an immune response against hepatitis b virus (hbv)

Country Status (12)

Country Link
EP (1) EP3727446A1 (en)
JP (1) JP2021506300A (en)
KR (1) KR20200100745A (en)
CN (1) CN111741766A (en)
AU (1) AU2018389786A1 (en)
BR (1) BR112020012273A2 (en)
CA (1) CA3086325A1 (en)
IL (1) IL275423A (en)
MA (1) MA51312A (en)
MX (1) MX2020006471A (en)
SG (1) SG11202005710YA (en)
WO (1) WO2019123250A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091513A1 (en) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION
EA202091516A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV)
US20220313815A1 (en) * 2019-06-20 2022-10-06 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (en) 1904-11-07 1905-03-14 William Waid Paddock Pressure filter
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
KR100427786B1 (en) 1997-04-03 2004-04-30 일렉트로우펙트 에이에스 Method and device for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
DE69826124T3 (en) 1997-06-30 2007-10-11 Institut Gustave Roussy ADMINISTRATION OF NUCLEIC ACID IN CROSS-LINKED MUSCLES
EP2428249B1 (en) 1998-07-13 2015-10-07 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
DE60014489T3 (en) 1999-05-17 2010-08-12 Crucell Holland B.V. Adenovirus-derived gene transfer vehicles containing at least one type adenovirus type 35 element
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
IL154712A0 (en) 2000-11-23 2003-10-31 Bavarian Nordic As Modified vaccinia ankara virus variant
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
JP4495588B2 (en) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー Stable adenoviral vector and method for propagation thereof
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
LT2163260T (en) 2004-01-23 2017-06-26 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
EP3466483A1 (en) 2004-03-08 2019-04-10 Ichor Medical Systems Inc. Improved apparatus for electrically mediated delivery of therapeutic agents
CN101248173A (en) * 2005-04-08 2008-08-20 墨尔本保健公司 Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
DK2066399T3 (en) 2006-10-17 2019-01-21 Inovio Pharmaceuticals Inc Electroporation devices and methods for using them for the electroporation of cells in mammals
US20110110974A1 (en) * 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
WO2010060632A1 (en) 2008-11-27 2010-06-03 Bavarian Nordic A/S Promoters for recombinant viral expression
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
SG172935A1 (en) 2009-02-02 2011-08-29 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
EP2461826A2 (en) * 2009-08-07 2012-06-13 Transgene SA Composition for treating hbv infection
EA029504B1 (en) 2010-12-14 2018-04-30 Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретэри Оф Дзе Департмент Оф Хелт Энд Хьюмэн Сервисиз Method of inducing and immune response against a filovirus antigen in a patient using serotype 26 and serotype 35 adenoviruses
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
UA118340C2 (en) 2012-10-28 2019-01-10 Баваріан Нордік А/С Pr13.5 promoter for robust t-cell and antibody responses
IL256869B (en) 2015-07-31 2022-07-01 Bavarian Nordic As Promoters for enhancing expression in poxvirus
WO2017121791A1 (en) * 2016-01-12 2017-07-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating hbv
KR102535764B1 (en) 2016-03-28 2023-05-30 아이커 메디칼 시스템스 인코포레이티드 Apparatus for delivery of therapeutic agents

Also Published As

Publication number Publication date
AU2018389786A1 (en) 2020-06-18
CN111741766A (en) 2020-10-02
CA3086325A1 (en) 2019-06-27
MA51312A (en) 2020-10-28
KR20200100745A (en) 2020-08-26
WO2019123250A1 (en) 2019-06-27
BR112020012273A2 (en) 2020-11-24
SG11202005710YA (en) 2020-07-29
EP3727446A1 (en) 2020-10-28
JP2021506300A (en) 2021-02-22
MX2020006471A (en) 2020-09-22

Similar Documents

Publication Publication Date Title
HK1255502A1 (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof
HK1255847A1 (en) Vaccines against hepatitis b virus
IL258697A (en) Crispr/cas-related methods and compositions for treating hepatitis b virus
ZA201906252B (en) Hepatitis b virus surface antigen inhibitor
IL275427A (en) Hepatitis b virus (hbv) vaccines and uses thereof
GB201708444D0 (en) Compositions and methods for inducing an immune response
HK1256869A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
HK1248278A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
IL275423A (en) Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
IL274298A (en) Amino-thaizole substituted indole-z-carboxamides and compositions comprising same for use against the hepatitis b virus (hbv)
IL275429A (en) Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
EP3463448A4 (en) Compositions and methods for generating an immune response to hepatitis b virus
HK1255379A1 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
IL290924A (en) Hepatitis b virus vaccines
GB201807932D0 (en) Compositions and methods for inducing an immune response
HK1259329A1 (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
EP3244922A4 (en) Methods of inducing an immune response to hepatitis c virus
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
GB201702193D0 (en) Hepatitis E virus vaccine
PL3244921T3 (en) An immunogenic vaccine against the hcv and/or hbv